SimBioSys

SimBioSys is a technology company based in Chicago, Illinois, specializing in computational oncology. Founded in 2018 at the University of Illinois Urbana-Champaign, the company focuses on transforming cancer care decision-making and enhancing patient experiences through advanced simulations and artificial intelligence. SimBioSys has developed TumorScope, a simulation engine that creates detailed virtual models of tumors using standard diagnostic data. This technology allows for precise predictions of therapy responses and insights into drug resistance, enabling personalized treatment planning. The company collaborates with over 130 oncologists and 16 premier cancer centers, including the University of Chicago and Mayo Clinic. Its initial focus is on early-stage breast cancer, where TumorScope aids in selecting optimal therapies. Validation studies have shown strong predictive accuracy, and SimBioSys is working towards FDA clearance for its surgical planning tool. The company aims to empower clinicians and patients by providing a comprehensive view of treatment options, ultimately striving to improve patient outcomes in cancer care.